Abbott HIV Test Demonstrates Earlier Disease Detection
Research presented at the American Association for Clinical Chemistry annual meeting shows that an assay developed by Abbott for simultaneous detection of both HIV antigens and antibodies reduced the detection window by zero to nine days in this study compared to HIV antibody-only assays. Earlier detection was shown on four of the five panels tested.
Cardiovascular
Pages: 1 [2]
FDA Approves Expanded Use Of ISENTRESS® (raltegravir) In Combination Therapy For Adult Patients With HIV-1 Infection
is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Forward-looking statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management"s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck"s business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck"s Form 10-K for the year ended Dec. 31, 2008, and in any risk factors or cautionary statements contained in the Company"s periodic reports on Form 10-Q or current reports on Form 8-K, which the Company incorporates by reference. ISENTRESS® is a registered trademark of Merck & Co., Inc. MerckPages: 1 [2]